Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Amaryl
Glimepiride · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Glimepiride | EXPERIMENTAL | Glimepiride tablets 1 mg of Dr. Reddy's Laboratories Limited |
| Amaryl | ACTIVE_COMPARATOR | Amaryl 1 mg tablets of Aventis Pharmaceuticals Inc |
| Name | Type | Description |
|---|---|---|
| Glimepiride | DRUG | Glimepiride tablets 1 mg |
| Glimepiride tablets 1 mg | DRUG | - |
Inclusion Criteria: * Male or non-child-bearing potential female,smoker and or non-smoker,18 years of age and older. * Capable of consent. * Non-child-bearing potential female subject: * Post-menopausal state:absence of menses for 12 months prior to drug. administration or hysterectomy with bilater...
Glimepiride is a small molecule drug developed by Dr. Reddy's Laboratories Ltd, which trades under the ticker RDY. It is being studied in Phase 1 clinical development. The specific medical conditions it is intended to treat have not been disclosed, and its therapeutic area is classified as other.
Glimepiride targets KCNJ11 and ABCC8. It is classified as a blocker of these targets. KCNJ11 and ABCC8 are the molecular targets named for this small molecule agent, which is being developed by Dr. Reddy's Laboratories Ltd.
Glimepiride is developed by Dr. Reddy's Laboratories Ltd, a company whose ticker symbol is RDY. Dr. Reddy's Laboratories Ltd is the sponsor behind the clinical studies of Glimepiride, including the bioequivalence trials conducted in healthy subjects.
Glimepiride is in Phase 1 clinical development. It is an investigational drug and is not approved. Two Phase 1 trials have been completed, and no trials are currently active. Both completed studies were bioequivalence studies conducted in healthy adult subjects.
Glimepiride has been studied in two completed Phase 1 trials. NCT01053689 was a bioequivalence study of Glimepiride 1 mg tablets in healthy subjects under fed conditions, and NCT01052909 was a bioequivalence study of Glimepiride tablets 1 mg under fasting conditions. Each trial enrolled 44 participants in Canada.